🇺🇸 FDA
Pipeline program

CT1812

COG0102

Phase 2 small_molecule completed

Quick answer

CT1812 for Alzheimer's Disease is a Phase 2 program (small_molecule) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
COGNITION THERAPEUTICS INC
Indication
Alzheimer's Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials